What is Kanjinti (trastuzumab-anns)?

Kanjinti™ (trastuzumab-anns) is an engineered biologic medication that is “biosimilar” to Herceptin®. Biosimilar medications are approved based on the similarity of their action to approved medications.

Kanjinti may be used in certain patients with HER2+ breast cancer, to be used either alone or in combination with other medicines. HER2+ breast cancer is characterized by tumors that overproduce a specific molecule known as human epidermal growth factor receptor-2, or HER2.

Kanjinti can be used against metastatic breast cancer or as adjuvant therapy after initial breast cancer treatment.1 Metastatic breast cancer refers to advanced breast cancer that has already spread to other parts of the body. Adjuvant therapy attempts to keep cancer from recurring after initial treatment, like surgery.1,2

Kanjinti is not available in generic forms.

What are the ingredients in Kanjinti?

The active ingredient in Kanjinti is trastuzumab-anns.2

How does Kanjinti work?

Kanjinti is one of several monoclonal antibodies used to treat breast cancer. Our bodies naturally produce antibodies, which are immune factors that act against bacteria, viruses, and other foreign organisms that invade and pose a threat to our health. Drugmakers have engineered a variety of antibodies to target the mechanisms that cause certain diseases, including breast cancer.

Certain breast cancer cells have large numbers of molecules called human epidermal growth factor receptor-2, or HER2, on their cell surfaces. These molecules stimulate abnormally fast cell growth. Like Herceptin, Kanjinti binds to and blocks these molecules, also killing the cancerous cells that carry them.1,3

Since Kanjinti works only with tumors with high levels of HER2, your doctor will test your tumor for it before prescribing this medication.

What are the possible side effects of Kanjinti?

Common side effects with Kanjinti include3:

  • Headache
  • Diarrhea
  • Nausea
  • Chills
  • Fever
  • Infection
  • Heart problems
  • Insomnia
  • Cough
  • Rash

In some patients, Kanjinti may cause more harmful, sometimes life-threatening side effects.
These include3:

  • Serious heart problems, including heart failure
  • Severe lung damage
  • Life-threatening reactions to the infusion
  • Serious allergic reactions
  • Worsening of chemotherapy-induced reductions in white blood cells

Kanjinti has been shown to harm fetuses, so it is important not to become pregnant or breastfeed while you are taking it. Women who can become pregnant who receive Kanjinti should use birth control during their treatment and for seven months after treatment with Kanjinti is completed (patients should discuss appropriate birth control methods with their doctor). This is not a complete list of all potential side effects of Kantinji. For more information, consult your doctor or healthcare provider. If you notice any new or worsening side effects, contact your doctor or healthcare provider immediately.

Things to note about Kanjinti

Before taking Kanjinti, tell your doctor about all your health conditions, including if you3:

  • Are allergic to trastuzumab or mouse proteins
  • Have or have had heart disease
  • Have or have had lung disease, a tumor in your lungs, or difficulty breathing
  • Are being treated with radiation therapy to the chest or with other chemotherapy medicines, since some medications don’t mix well with Kanjinti
  • Are pregnant or plan to become pregnant or are breastfeeding

Before starting treatment with Kanjinti, patients should talk to their doctor about all medications (prescription and over-the-counter), vitamins, and herbal supplements they are taking. Some medications or supplements may interfere with each other and may cause side effects. It is important for doctors to test your heart function before and regularly during therapy with Kanjinti since it can cause serious heart problems.

Receiving Kanjinti

Kanjinti is given through a vein in your arm via intravenous infusion. It must be administered by a healthcare provider at a medical office. The first infusion is given over 90 minutes, to be sure you are tolerating the medication well. After that, it may potentially be given over 30 minutes.3

Your doctor will determine the appropriate dosing regimen and administration schedule for you. When used as adjuvant therapy, Kanjinti is generally given in conjunction with other chemotherapy medications. Other additional treatments, such as chemotherapy, will take additional time for infusion administration when given in combination with Kanjinti infusion.

For more information about Kanjinti, read the complete prescribing information.

Patients should talk to their doctor if they have any questions, or if they have questions regarding their Kanjinti regimen.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

Written by: Editorial Team | Last reviewed: October 2020.